Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the body’s immune system attacks its own tissues. About 50% of people with lupus develop this complication, making it one of the most common and serious consequences of the disease. Up to 60% of adults and 80% of children with lupus will experience some degree of kidney involvement during their lifetime, and without treatment, it can progress to kidney failure.
How Lupus Damages the Kidneys
In lupus, the immune system produces antibodies that mistakenly target the body’s own cells. When cells die naturally (a normal process called apoptosis), their internal components, particularly DNA-protein bundles called nucleosomes, are supposed to be quietly cleaned up. In lupus, this cleanup process is impaired. The leftover cellular debris circulates in the bloodstream and eventually gets trapped in the tiny filtering units of the kidneys, called glomeruli.
Once lodged there, these debris fragments attract the autoantibodies lupus produces, forming clumps known as immune complexes. The immune system then mounts a full inflammatory response against these deposits, activating a chain reaction that recruits inflammatory cells, generates tissue-damaging molecules, and can even punch holes in kidney cell membranes. Over time, this repeated assault scars the delicate filtering structures of the kidney and impairs their ability to clean your blood.
Symptoms and Warning Signs
In its early stages, lupus nephritis often produces no noticeable symptoms. Many people first learn about it through routine blood or urine tests ordered by their doctor. As the disease progresses, signs may include foamy urine (from protein leaking into it), swelling in the legs, ankles, or around the eyes, increased urination, and waking at night to urinate.
When kidney inflammation becomes more severe, high blood pressure is common and may cause headaches, dizziness, or visual disturbances. Heavy protein loss through the kidneys (more than 3.5 grams per day) can lead to a condition called nephrotic syndrome, where fluid accumulates throughout the body, causing significant swelling in the legs, fluid buildup in the abdomen, and even fluid around the heart or lungs. Some people also notice blood in their urine, though it’s often only visible under a microscope.
Because lupus nephritis is part of a systemic disease, it usually appears alongside other lupus symptoms: the characteristic butterfly-shaped facial rash, joint pain, fatigue, fever, and sensitivity to sunlight.
Who Is Most at Risk
Lupus itself is about six times more common in women than in men, and lupus nephritis follows the same pattern. Black women face nearly double the prevalence of lupus compared to white women, with a rate of about 286 per 100,000. American Indian and Alaska Native populations carry a similarly high disease burden, though this is less widely recognized.
Geography and socioeconomic status also play a role. In the United States, lupus prevalence is highest in the South and lowest in the Northeast. People living in lower-income zip codes have higher rates of lupus and are more likely to see their kidney disease progress. Black race, Hispanic ethnicity, and poverty are all independently associated with worse lupus nephritis outcomes, driven in part by reduced access to care and lower rates of medication adherence.
How It Is Diagnosed
Doctors typically detect lupus nephritis through a combination of urine tests, blood work, and a kidney biopsy. A urinalysis that shows protein, blood, or specific cellular formations called red blood cell casts is a strong signal. Blood tests usually reveal low levels of complement proteins (C3 and C4, parts of the immune system consumed during the inflammatory attack) and the presence of anti-double-stranded DNA antibodies, both hallmarks of active lupus.
A kidney biopsy, where a small tissue sample is taken with a needle, remains the gold standard. It reveals the pattern and severity of inflammation and is used to classify the disease into one of several classes (I through VI), ranging from minimal involvement to advanced scarring. This classification directly guides treatment decisions. Class IV (diffuse inflammation) is the most common severe form and carries the highest risk of kidney failure.
Treatment Approach
Treatment for lupus nephritis typically unfolds in two phases: an initial aggressive phase to bring the inflammation under control, followed by a longer maintenance phase to keep it from returning.
During the initial phase, which usually lasts about six months, the standard approach involves immune-suppressing medications combined with corticosteroids to rapidly reduce inflammation. The two main options for this phase are mycophenolate mofetil (an immune suppressant taken by mouth) and cyclophosphamide (a stronger agent given intravenously). Randomized clinical trials have shown that mycophenolate performs comparably to cyclophosphamide for most patients, and it is now commonly recommended as the first-line choice due to a more favorable side-effect profile. Once inflammation is controlled, maintenance therapy with either mycophenolate or azathioprine continues for years.
Two newer therapies have been approved specifically for lupus nephritis, both used alongside standard treatment. Belimumab, approved in December 2020, was the first drug ever approved by the FDA specifically for active lupus nephritis. It works by blocking a protein that helps certain immune cells survive, reducing the production of harmful antibodies. Voclosporin, a calcineurin inhibitor, was approved shortly after and works by dampening the immune response at a different point in the chain. Both are added on top of existing regimens rather than replacing them.
Dietary Changes That Help
When lupus nephritis begins to impair kidney function, dietary adjustments become an important part of management. The two biggest levers are sodium and protein.
Kidney guidelines consistently recommend keeping sodium intake below 2 grams per day (about 5 grams of table salt) for people with kidney disease and high blood pressure. Reducing sodium helps control blood pressure and can also reduce protein leakage in the urine, working alongside medications. In practical terms, this means limiting processed foods, canned soups, restaurant meals, and salty snacks.
Protein recommendations depend on how much kidney function has been lost. In the earlier stages, intake of about 0.8 grams of protein per kilogram of body weight per day is generally advised. For someone weighing 70 kilograms (about 154 pounds), that works out to roughly 56 grams of protein daily. As kidney disease advances, lower protein targets of 0.6 to 0.8 grams per kilogram may be recommended. It’s important to get enough calories (30 to 35 per kilogram per day) when reducing protein to prevent muscle wasting.
Long-Term Outlook
The prognosis for lupus nephritis has improved substantially over the past several decades, though it remains a serious condition. Between 10% and 30% of people with lupus nephritis eventually progress to end-stage kidney failure requiring dialysis or transplant. In developed countries, the five-year risk of reaching that point dropped from about 16% in the 1970s to around 11% by the mid-1990s, where it has roughly plateaued.
The outlook varies significantly depending on the class of disease. Class IV lupus nephritis, the most aggressive form, carries a five-year risk of kidney failure around 19% and a 15-year risk of 44%. Class V, a membranous pattern that primarily causes heavy protein loss, has a lower five-year risk of about 4% but still reaches 20% at 15 years. Kidney disease remains the single most important predictor of death in people with lupus overall.
Early detection matters enormously. Because lupus nephritis is often silent in its early stages, regular urine and blood monitoring is essential for anyone with lupus. Catching kidney involvement before significant damage accumulates gives treatment the best chance of preserving kidney function long term.